22 October 2009
Ian Haydock
ian.haydock@informa.com
With sales growth for biologics expected to outpace that in the overall pharma sector over the next few years, it is not surprising that big pharma has been beefing up its presence in the sector through acquisitions and licensing deals.
What might be more surprising is that large R&D-based...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Merck & Co moves ahead in biosimilars through Hanwha deal
- US Capitol Capsule: Group proposes efforts to ensure US innovation competitiveness
- Sanofi, Pfizer, Takeda, or Roche fit partner profile for Amylin's exenatide
- US Capitol Capsule: Patent reform done, but will it create jobs?
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
